We write to express our deep concern with reports about proposed provisions regarding intellectual property, investment and pharmaceuticals reimbursement in the Trans-Pacific Partnership negotiations (TPP). We believe those provisions if included in the final agreement, would severely threaten access to affordable medicines in the Asia-Pacific region, particularly in developing countries, and could have potentially serious consequences for patients in developed countries, including the United States.
A series of reports suggest that those provisions would go beyond the obligations under the Trade-Related Aspect of Intellectual Property Agreement (TRIPS) and would backtrack from the principles in the Bipartisan Agreement of May 10, 2007. Such measures could limit generic competition, lead to higher drug prices, and compromise access to affordable medicines.
Click here for the full letter (PDF)
QUT Media4th November 2025 The United Kingdom Parliament is considering a bill aimed at making smoking obsolete, which has been
Speaking at the Global Expert Network on Copyright User Rights Symposium on 16 June 2025, Professor Christophe Geiger argues for
On 25 September 2025, Professor Wend Wendland, delivered the 14th Peter Jaszi Distinguished Lecture at American University in Washington D.C..
On September 18, 2025, the Italian Senate definitively approved the country’s first comprehensive framework law on artificial intelligence (AI). The
Por Andrés Izquierdo Durante la segunda semana de agosto, fui invitado a hablar en la Feria Internacional del Libro de
By Andrés Izquierdo AI, Copyright, and the Future of Creativity: Notes from the Panama International Book FairDuring the second week